Synexo Group (SYNEXO) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
28 Nov, 2025Executive summary
Q3 2025 marked a transformational period with the completion of a reverse takeover, relisting on NGM Nordic SME, and integration of Backupbuddy AS and Backupbanken AS into the Group.
The Group shifted from legacy electronics to a Nordic-focused BaaS and data-security platform, with a new board and CEO, and a SEK 55m directed share issue strengthening the balance sheet.
The business model is now a pure-play BaaS platform with recurring, contract-driven revenues, distributed via over 100 IT-service partners, targeting SMEs and healthcare.
Financial highlights
Pro forma Q3 2025 revenue was SEK 1.04m, up 56% year-over-year; gross margin reached 63%.
Pro forma EBITDA for operating subsidiaries was nearly break-even at SEK -2k, a significant improvement from SEK -298k in Q3 2024.
Statutory Q3 2025 net sales were SEK 0.5m, EBIT SEK -1.0m, and profit after tax SEK -1.0m, distorted by transaction structure and one-off costs.
Group equity ratio stands at 96% with no long-term interest-bearing liabilities and strong liquidity (cash SEK 3.1m as of 30 Sep 2025).
Outlook and guidance
Entering Q4, the Group has strong operational momentum, increasing ARR visibility, and ongoing efficiency gains.
Focus remains on disciplined growth, operational efficiency, and M&A to consolidate the fragmented Nordic BaaS market.
Monthly reporting of key operating metrics will commence from Q4 2025.
Latest events from Synexo Group
- ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 202526 Feb 2026 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation2 Jan 2026 - No operations remain after subsidiary sale; future depends on a pending data storage acquisition.SYNEXO
Q2 202521 Aug 2025 - Sales dropped sharply and losses deepened, with recovery delayed to 2025/2026.SYNEXO
Q3 202413 Jun 2025 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 202413 Jun 2025 - Sales up, losses persist; MedTech order and new partnerships drive future focus.SYNEXO
Q1 20256 Jun 2025 - Omsättning föll 39% och fortsatt förlust kräver ny finansiering och omstrukturering.SYNEXO
Q4 20245 Jun 2025